Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients

Details

Serval ID
serval:BIB_78A35C7DC774
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients
Journal
British Journal of Cancer
Author(s)
Azria  D., Gourgou  S., Sozzi  W. J., Zouhair  A., Mirimanoff  R. O., Kramar  A., Lemanski  C., Dubois  J. B., Romieu  G., Pelegrin  A., Ozsahin  M.
ISSN
0007-0920 (Print)
Publication state
Published
Issued date
10/2004
Volume
91
Number
7
Pages
1251-60
Notes
Clinical Trial
Journal Article
Multicenter Study --- Old month value: Oct 4
Abstract
Concomitant use of adjuvant tamoxifen (TAM) and radiation therapy (RT) is not widely accepted. We aim to assess whether this treatment is associated with an increased risk of developing subcutaneous fibrosis after conservative or radical surgery in breast cancer patients. We analysed 147 women with breast cancer treated with adjuvant RT, and who were included in the KFS 00539-9-1997/SKL 00778-2-1999 prospective study aimed at evaluating the predictive value of CD4 and CD8 T-lymphocyte apoptosis for the development of radiation-induced late effects. TAM (20 mg day(-1)) with concomitant RT was prescribed in 90 hormone receptor-positive patients. There was a statistically significant difference in terms of complication-relapse-free survival (CRFS) rates at 3 years, 48% (95% CI 37.2-57.6%) vs 66% (95% CI 49.9-78.6%) and complication-free survival (CFS) rates at 2 years, 51% (95% CI 40-61%) vs 80% (95% CI 67-89%) in the TAM and no-TAM groups, respectively. In each of these groups, the CRFS rates were significantly lower for patients with low levels of CD8 radiation-induced apoptosis, 20% (95% CI 10-31.9%), 66% (95% CI 51.1-77.6%), and 79% (95% CI 55-90.9%) for CD8 </=16, 16-24, and >24%, respectively. Similar results were observed for the CFS rates. The concomitant use of TAM with RT is significantly associated with an increased incidence of grade 2 or greater subcutaneous fibrosis; therefore, caution is needed for radiosensitive patients.
Keywords
Adult Aged Aged, 80 and over Antineoplastic Agents, Hormonal/*adverse effects/*therapeutic use Apoptosis Breast Neoplasms/*drug therapy/*radiotherapy CD4-Positive T-Lymphocytes CD8-Positive T-Lymphocytes Combined Modality Therapy Disease-Free Survival Female Humans Middle Aged Prospective Studies Radiation Pneumonitis/*etiology Risk Factors Tamoxifen/*adverse effects/*therapeutic use
Pubmed
Web of science
Open Access
Yes
Create date
24/01/2008 17:20
Last modification date
20/08/2019 14:35
Usage data